Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
This study is currently recruiting participants.
Verified April 2013 by National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
First received: July 26, 2002
Last updated: April 3, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD; the PACTG P1026s Study Team. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28;20(4):553-560.
Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS; for the PACTG 1026s study team. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 3;20(15):1931-1939.
Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV; the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2009 Dec 3; [Epub ahead of print]